Abca1tm1Jp/Abca1tm1Jp
Abcg1tm1Tall/Abcg1tm1Tall
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6
|
abnormal bone marrow cell morphology/development |
J:190966
|
|
increased interleukin-17 secretion |
J:190966
|
|
increased interleukin-23 secretion |
J:190966
|
Adam17tm1Bbl/Adam17tm1Bbl
Lyz2tm1(cre)Ifo/0
involves: 129P2/OlaHsd
|
abnormal macrophage physiology |
J:139846
|
|
decreased circulating tumor necrosis factor level |
J:139846
|
|
decreased susceptibility to endotoxin shock |
J:139846
|
Adcy7tm1.1Pcst/Adcy7tm1.1Pcst
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6J
|
increased tumor necrosis factor secretion |
J:191067
|
|
peritoneal inflammation |
J:191067
|
Adora2btm1Msit/Adora2btm1Msit
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6
|
decreased susceptibility to injury |
J:169155
|
Apba3tm1.1Ski/Apba3tm1.1Ski
Lyz2tm1(cre)Ifo/Lyz2+
B6.129-Apba3tm1.1Ski Lyz2tm1(cre)Ifo
|
decreased susceptibility to endotoxin shock |
J:176742
|
|
decreased susceptibility to xenobiotic induced morbidity/mortality |
J:176742
|
Apoetm1Bres/Apoetm1Bres
Bcl2tm1Irt/Bcl2tm1Irt
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6
|
atherosclerotic lesions |
J:144243
|
|
normal
cardiovascular system phenotype |
J:144243
|
|
normal
homeostasis/metabolism phenotype |
J:144243
|
|
increased macrophage apoptosis |
J:144243
|
Apoetm1Lmh/Apoetm1Lmh
Ldlrtm1Her/Ldlrtm1Her
Lrp1tm2Her/Lrp1tm2Her
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S7/SvEvBrd
|
atherosclerotic lesions |
J:129557
|
|
increased susceptibility to atherosclerosis |
J:129557
|
Arg1tm1Pmu/Arg1tm1Pmu
Lyz2tm1(cre)Ifo/?
B6.Cg-Arg1tm1Pmu Lyz2tm1(cre)Ifo
|
decreased susceptibility to parasitic infection |
J:143229
|
Arih1em3Gpt/Arih1em3Gpt
Lyz2em1(icre)Gpt/Lyz2+
C57BL/6JGpt-Arih1em3Gpt Lyz2em1(icre)Gpt
|
decreased circulating interferon-beta level |
J:330879
|
|
decreased circulating interleukin-6 level |
J:330879
|
|
decreased interferon-beta secretion |
J:330879
|
|
decreased interleukin-6 secretion |
J:330879
|
|
normal
immune system phenotype |
J:330879
|
|
increased susceptibility to Herpesvirales infection |
J:330879
|
|
increased susceptibility to Herpesvirales infection induced morbidity/mortality |
J:330879
|
Arih1em3Gpt/Arih1em3Gpt
Lyz2em1(icre)Gpt/Lyz2+
Trex1em1Gpt/Trex1em1Gpt
C57BL/6JGpt-Arih1em3Gpt Trex1em1Gpt Lyz2em1(icre)Gpt
|
normal
growth/size/body region phenotype |
J:330879
|
|
normal
immune system phenotype |
J:330879
|
|
normal
mortality/aging |
J:330879
|
Atf3tm1.1Hai/Atf3tm1.1Hai
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * FVB/N
|
decreased metastatic potential |
J:201626
|
Atg5tm1Myok/Atg5tm1Myok
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S/SvEv
|
abnormal circulating chemokine level |
J:235399
|
|
abnormal kidney morphology |
J:235399
|
|
abnormal macrophage physiology |
J:235399
|
|
abnormal renal glomerulus morphology |
J:235399
|
|
decreased body weight |
J:235399
|
|
decreased circulating interleukin-10 level |
J:235399
|
|
glomerulonephritis |
J:235399
|
|
increased anti-double stranded DNA antibody level |
J:235399
|
|
increased anti-nuclear antigen antibody level |
J:235399
|
|
increased autoantibody level |
J:235399
|
|
increased blood urea nitrogen level |
J:235399
|
|
increased circulating creatinine level |
J:235399
|
|
increased circulating interleukin-1 beta level |
J:235399
|
|
increased circulating interleukin-6 level |
J:235399
|
|
increased circulating interleukin-12b level |
J:235399
|
|
increased IgG level |
J:235399
|
|
increased lymphocyte cell number |
J:235399
|
|
increased monocyte cell number |
J:235399
|
|
increased neutrophil cell number |
J:235399
|
|
increased susceptibility to systemic lupus erythematosus |
J:235399
|
|
increased urine protein level |
J:235399
|
Atg7tm1Tchi/Atg7tm1Tchi
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6NCrlj * CBA/JNCrlj
|
abnormal circulating chemokine level |
J:235399
|
|
abnormal kidney morphology |
J:235399
|
|
abnormal macrophage physiology |
J:235399
|
|
abnormal renal glomerulus morphology |
J:235399
|
|
decreased body weight |
J:235399
|
|
decreased circulating interleukin-10 level |
J:235399
|
|
glomerulonephritis |
J:235399
|
|
increased anti-double stranded DNA antibody level |
J:235399
|
|
increased anti-nuclear antigen antibody level |
J:235399
|
|
increased autoantibody level |
J:235399
|
|
increased blood urea nitrogen level |
J:235399
|
|
increased circulating creatinine level |
J:235399
|
|
increased circulating interleukin-1 beta level |
J:235399
|
|
increased circulating interleukin-6 level |
J:235399
|
|
increased circulating interleukin-12b level |
J:235399
|
|
increased IgG level |
J:235399
|
|
increased lymphocyte cell number |
J:235399
|
|
increased monocyte cell number |
J:235399
|
|
increased neutrophil cell number |
J:235399
|
|
increased susceptibility to systemic lupus erythematosus |
J:235399
|
|
increased urine protein level |
J:235399
|
Atg7tm1Tchi/Atg7tm1Tchi
Lyz2tm1(cre)Ifo/Lyz2+
Tg(CAG-EGFP/Map1lc3b)53Nmz/0
involves: 129P2/OlaHsd * C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj * DBA/2
|
abnormal circulating chemokine level |
J:235399
|
|
abnormal macrophage physiology |
J:235399
|
|
decreased circulating interleukin-10 level |
J:235399
|
|
increased circulating interleukin-1 beta level |
J:235399
|
|
increased circulating interleukin-6 level |
J:235399
|
Atg16l1tm2.1Mvlc/Atg16l1tm2.1Mvlc
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6
|
impaired autophagy |
J:206931
|
Bcap31tm1.1Bwang/Bcap31tm1.1Bwang
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6
|
abnormal enzyme/coenzyme level |
J:292505
|
|
abnormal spatial reference memory |
J:292505
|
|
normal
behavior/neurological phenotype |
J:292505
|
|
decreased neuron number |
J:292505
|
|
increased inflammatory response |
J:292505
|
|
increased interleukin-1 beta secretion |
J:292505
|
|
increased microglial cell activation |
J:292505
|
|
increased tumor necrosis factor secretion |
J:292505
|
Bcl2tm1Irt/Bcl2tm1Irt
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6
|
increased macrophage apoptosis |
J:144243
|
Becn1tm1Ebr/Becn1tm1Ebr
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd
|
abnormal circulating chemokine level |
J:235399
|
|
abnormal kidney morphology |
J:235399
|
|
abnormal macrophage physiology |
J:235399
|
|
abnormal renal glomerulus morphology |
J:235399
|
|
abnormal spleen morphology |
J:235399
|
|
decreased body weight |
J:235399
|
|
decreased circulating interleukin-10 level |
J:235399
|
|
glomerulonephritis |
J:235399
|
|
increased anti-double stranded DNA antibody level |
J:235399
|
|
increased anti-nuclear antigen antibody level |
J:235399
|
|
increased autoantibody level |
J:235399
|
|
increased blood urea nitrogen level |
J:235399
|
|
increased circulating creatinine level |
J:235399
|
|
increased circulating interleukin-1 beta level |
J:235399
|
|
increased circulating interleukin-6 level |
J:235399
|
|
increased circulating interleukin-12b level |
J:235399
|
|
increased IgG level |
J:235399
|
|
increased lymphocyte cell number |
J:235399
|
|
increased monocyte cell number |
J:235399
|
|
increased neutrophil cell number |
J:235399
|
|
increased susceptibility to systemic lupus erythematosus |
J:235399
|
|
increased urine protein level |
J:235399
|
Casp8tm1Wll/Casp8tm1.1Yuan
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129S1/Sv * 129X1/SvJ * MF1
|
abnormal macrophage differentiation |
J:92722
|
Ccl2tm1.1Pame/Ccl2tm1.1Pame
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6
|
normal
immune system phenotype |
J:171379
|
Ccr2tm1Mpa/Ccr2tm1Mpa
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6 * CBA
|
abnormal wound healing |
J:189044
|
|
decreased macrophage cell number |
J:189044
|
Cd1d1tm1.1Aben/Cd1d1tm1.1Aben
Lyz2tm1(cre)Ifo/Lyz2+
B6.Cg-Cd1d1tm1.1Aben Lyz2tm1(cre)Ifo
|
decreased interferon-gamma secretion |
J:183087
|
|
decreased interleukin-4 secretion |
J:183087
|
|
normal
immune system phenotype |
J:183087
|
Cdkn2btm1Wff/Cdkn2btm1Wff
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6
|
abnormal common myeloid progenitor cell morphology |
J:163498
|
|
abnormal megakaryocyte progenitor cell morphology |
J:163498
|
|
decreased erythroid progenitor cell number |
J:163498
|
|
increased monocyte cell number |
J:163498
|
|
myeloid hyperplasia |
J:163498
|
Cebpbtm1.1Elgaz/Cebpbtm1.1Elgaz
Lyz2em1.1(cre)Elgaz/Lyz2+
BALB/cJ-Cebpbtm1.1Elgaz Lyz2em1.1Elgaz/Elgaz
|
abnormal myeloid cell number |
J:247885
|
|
decreased circulating interleukin-10 level |
J:247885
|
|
decreased susceptibility to bacterial infection |
J:247885
|
|
decreased susceptibility to bacterial infection induced morbidity/mortality |
J:247885
|
|
decreased transforming growth factor beta level |
J:247885
|
|
increased circulating interleukin-6 level |
J:247885
|
|
increased circulating tumor necrosis factor level |
J:247885
|
Cers6tm1Arte/Cers6tm1Arte
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6N
|
normal
homeostasis/metabolism phenotype |
J:215519
|
Cflartm1.1Pope/Cflartm1.2Pope
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd
|
abnormal abdominal lymph node morphology |
J:167430
|
|
abnormal B cell number |
J:167430
|
|
abnormal bone marrow cell number |
J:167430
|
|
abnormal CD4-positive, alpha-beta T cell number |
J:167430
|
|
abnormal CD8-positive, alpha-beta T cell number |
J:167430
|
|
abnormal definitive hematopoiesis |
J:167430
|
|
abnormal erythropoiesis |
J:167430
|
|
abnormal lymphocyte cell number |
J:167430
|
|
abnormal myelopoiesis |
J:167430
|
|
abnormal spleen B cell follicle morphology |
J:167430
|
|
abnormal spleen marginal zone morphology |
J:167430
|
|
abnormal spleen morphology |
J:167430
|
|
abnormal spleen red pulp morphology |
J:167430
|
|
abnormal thymus corticomedullary boundary morphology |
J:167430
|
|
abnormal thymus morphology |
J:167430
|
|
anemia |
J:167430
|
|
decreased body size |
J:167430
|
|
decreased macrophage cell number |
J:167430
|
|
enlarged spleen |
J:167430
|
|
increased CD8-positive, alpha-beta T cell number |
J:167430
|
|
increased eosinophil cell number |
J:167430
|
|
increased granulocyte number |
J:167430
|
|
increased leukocyte cell number |
J:167430
|
|
increased monocyte cell number |
J:167430
|
|
increased neutrophil cell number |
J:167430
|
|
premature death |
J:167430
|
|
thrombocytosis |
J:167430
|
Cfptm2.1Song/Cfptm2.1Song
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129 * 129P2/OlaHsd * C57BL/6 * SJL
|
decreased susceptibility to induced arthritis |
J:165497
|
|
impaired complement alternative pathway |
J:165497
|
Chuktm1Lex/Chuktm1Lex
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S/SvEvBrd
|
impaired macrophage chemotaxis |
J:159873
|
|
impaired neutrophil chemotaxis |
J:159873
|
|
impaired neutrophil recruitment |
J:159873
|
Clec7atm1.1Bpip/Clec7atm1.1Bpip
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6J
|
abnormal macrophage physiology |
J:203908
|
|
decreased tumor necrosis factor secretion |
J:203908
|
|
impaired macrophage phagocytosis |
J:203908
|
|
increased susceptibility to fungal infection |
J:203908
|
Clstn3tm1c(EUCOMM)Hmgu/Clstn3tm1c(EUCOMM)Hmgu
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N * SJL
|
normal
limbs/digits/tail phenotype |
J:293885
|
Ctnnb1tm1Mmt/Ctnnb1+
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129X1/SvJ
|
abnormal osteoclast differentiation |
J:178340
|
|
decreased bone marrow cell number |
J:178340
|
|
decreased bone resorption |
J:178340
|
|
increased bone volume |
J:178340
|
|
normal
skeleton phenotype |
J:178340
|
Ctnnb1tm2Kem/Ctnnb1+
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ
|
decreased trabecular bone volume |
J:178340
|
|
increased bone resorption |
J:178340
|
|
increased osteoclast cell number |
J:178340
|
|
osteoporosis |
J:178340
|
Ctnnb1tm2Kem/Ctnnb1tm2Kem
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ
|
decreased trabecular bone volume |
J:178340
|
|
increased bone resorption |
J:178340
|
|
increased osteoclast cell number |
J:178340
|
|
osteoporosis |
J:178340
|
Cxcr4tm2Yzo/Cxcr4tm2Yzo
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6
|
normal
adipose tissue phenotype |
J:217569
|
|
normal
growth/size/body region phenotype |
J:217569
|
|
increased lymphocyte cell number |
J:217569
|
|
increased monocyte cell number |
J:217569
|
|
increased neutrophil cell number |
J:217569
|
Cybbtm1.1Abk/Cybbtm1.1Abk
Lyz2tm1(cre)Ifo/?
B6.Cg-Lyz2tm1(cre)Ifo Cybbtm1.1Abk
|
abnormal cued conditioning behavior |
J:245699
|
|
abnormal macrophage chemotaxis |
J:245699
|
|
decreased body length |
J:245699
|
|
decreased body weight |
J:245699
|
|
decreased cholesterol level |
J:245699
|
|
decreased circulating insulin level |
J:245699
|
|
decreased circulating LDL cholesterol level |
J:245699
|
|
decreased fasting circulating glucose level |
J:245699
|
|
decreased fat cell size |
J:245699
|
|
decreased susceptibility to diet-induced obesity |
J:245699
|
|
decreased triglyceride level |
J:245699
|
|
enlarged spleen |
J:245699
|
|
increased brain size |
J:245699
|
|
increased circulating HDL cholesterol level |
J:245699
|
|
increased epididymal fat pad weight |
J:245699
|
Cyribtm1c(KOMP)Wtsi/Cyribtm1d(KOMP)Wtsi
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S4/SvJaeSor * BcA17/Skmn * C57BL/6N
|
abnormal actin cytoskeleton morphology |
J:282597
|
|
abnormal circulating chemokine level |
J:282597
|
|
abnormal neutrophil physiology |
J:282597
|
|
increased circulating CXCL10 level |
J:282597
|
|
increased circulating interleukin-6 level |
J:282597
|
|
increased circulating interleukin-10 level |
J:282597
|
|
increased circulating tumor necrosis factor level |
J:282597
|
|
increased susceptibility to bacterial infection induced morbidity/mortality |
J:282597
|
|
pulmonary parenchymal consolidation |
J:282597
|
Ddx41tm1.1Arte/Ddx41tm1.1Arte
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6N
|
normal
hematopoietic system phenotype |
J:265023
|
|
normal
immune system phenotype |
J:265023
|
|
increased susceptibility to Retroviridae infection |
J:265023
|
Elavl1tm1.1Bndr/Elavl1tm1.1Bndr
Lyz2tm1(cre)Ifo/Lyz2+
B6.129-Elavl1tm1.1Bndr
|
abnormal blood circulation |
J:182000
|
|
abnormal capillary morphology |
J:182000
|
|
abnormal physiological neovascularization |
J:182000
|
|
cellular necrosis |
J:182000
|
Elavl1tm1.1Dkon/Elavl1tm1.1Dkon
Lyz2tm1(cre)Ifo/Lyz2+
B6.129P2-Elavl1tm1.1Dkon Lyz2tm1(cre)Ifo
|
abnormal macrophage chemotaxis |
J:184388
|
|
normal
immune system phenotype |
J:184388
|
|
increased circulating interleukin-1 beta level |
J:184388
|
|
increased circulating interleukin-6 level |
J:184388
|
|
increased circulating interleukin-12 level |
J:184388
|
|
increased circulating tumor necrosis factor level |
J:184388
|
|
increased colon adenocarcinoma incidence |
J:184388
|
|
increased colon adenoma incidence |
J:184388
|
|
increased incidence of tumors by chemical induction |
J:184388
|
|
increased macrophage cell number |
J:184388
|
|
increased monocyte cell number |
J:184388
|
|
increased susceptibility to endotoxin shock |
J:184388
|
|
increased susceptibility to induced colitis |
J:184388
|
|
increased susceptibility to xenobiotic induced morbidity/mortality |
J:184388
|
|
increased tumor growth/size |
J:184388
|
Elavl1tm1.1Dkon/Elavl1tm1.1Dkon
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6J
|
normal
immune system phenotype |
J:184388
|
|
increased circulating interleukin-1 beta level |
J:184388
|
|
increased circulating interleukin-6 level |
J:184388
|
|
increased circulating interleukin-12 level |
J:184388
|
|
increased circulating tumor necrosis factor level |
J:184388
|
|
increased susceptibility to endotoxin shock |
J:184388
|
|
increased susceptibility to xenobiotic induced morbidity/mortality |
J:184388
|
Engtm2.1Hma/Engtm2.1Hma
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd
|
normal
cardiovascular system phenotype |
J:212952
|
Esr1tm1.1Scma/Esr1tm1.1Scma
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6
|
abnormal osteoclast physiology |
J:156947
|
|
abnormal skeleton development |
J:156947
|
|
abnormal trabecular bone morphology |
J:156947
|
|
decreased compact bone mass |
J:156947
|
|
increased osteoclast cell number |
J:156947
|
Esr2tm1.1Pcn/Esr2tm1.1Pcn
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S2/SvPas
|
delayed wound healing |
J:165719
|
Fmnl1tm1.2Sdb/Fmnl1tm1.2Sdb
Lyz2tm1(cre)Ifo/Lyz2tm1(cre)Ifo
involves: C3H * C57BL/6 * FVB/N
|
abnormal Kupffer cell morphology |
J:250144
|
|
abnormal macrophage morphology |
J:250144
|
|
abnormal macrophage physiology |
J:250144
|
|
normal
cardiovascular system phenotype |
J:250144
|
|
decreased macrophage cell number |
J:250144
|
|
normal
growth/size/body region phenotype |
J:250144
|
|
normal
hematopoietic system phenotype |
J:250144
|
|
impaired macrophage chemotaxis |
J:250144
|
|
normal
mortality/aging |
J:250144
|
|
normal
reproductive system phenotype |
J:250144
|
Fntbtm1.1Mbrg/Fntbtm1.2Mbrg
Krastm4Tyj/Kras+
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S4/SvJae * BALB/cJ * C57BL/6 * FVB/N
|
decreased tumor growth/size |
J:158937
|
|
increased lung tumor incidence |
J:158937
|
|
increased lung weight |
J:158937
|
|
premature death |
J:158937
|
Fntbtm1.1Mbrg/Fntbtm1.2Mbrg
Krastm4Tyj/Kras+
Pggt1btm1Mbrg/Pggt1btm1.1Mbrg
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S4/SvJae * BALB/cJ * C57BL/6 * FVB/N
|
decreased tumor growth/size |
J:158937
|
|
increased lung tumor incidence |
J:158937
|
|
premature death |
J:158937
|
Fostm7Wag/Fostm7Wag
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6
|
decreased interleukin-10 secretion |
J:175064
|
|
increased circulating interleukin-6 level |
J:175064
|
|
increased circulating interleukin-10 level |
J:175064
|
|
increased circulating tumor necrosis factor level |
J:175064
|
|
increased interleukin-6 secretion |
J:175064
|
|
increased susceptibility to endotoxin shock |
J:175064
|
|
increased tumor necrosis factor secretion |
J:175064
|
Fosl2tm2Wag/Fosl2tm2Wag
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6
|
abnormal osteoclast differentiation |
J:137646
|
Fpr2tm1.1Jimw/Fpr2tm1.1Jimw
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129X1/SvJ
|
decreased susceptibility to induced colitis |
J:197568
|
Gba1tm1Clk/Gba1tm1.1Clk
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6J
|
abnormal enzyme/coenzyme activity |
J:117763
|
Gt(ROSA)26Sortm1(CAG-CAMK2G*T287D,-EGFP)Whua/Gt(ROSA)26Sor+
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129 * C57BL/6
|
normal
digestive/alimentary phenotype |
J:243363
|
Gt(ROSA)26Sortm1(OVAL/fla,GFP)Vnce/Gt(ROSA)26Sor+
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6J
|
abnormal circulating cytokine level |
J:260047
|
|
abnormal renal glomerulus morphology |
J:260047
|
|
anemia |
J:260047
|
|
decreased B cell number |
J:260047
|
|
decreased body size |
J:260047
|
|
decreased body weight |
J:260047
|
|
decreased hematocrit |
J:260047
|
|
decreased lymphocyte cell number |
J:260047
|
|
enlarged lymph nodes |
J:260047
|
|
enlarged spleen |
J:260047
|
|
glomerulonephritis |
J:260047
|
|
increased inflammatory response |
J:260047
|
|
increased monocyte cell number |
J:260047
|
|
increased neutrophil cell number |
J:260047
|
|
increased T cell number |
J:260047
|
|
joint inflammation |
J:260047
|
|
joint swelling |
J:260047
|
|
small intestinal inflammation |
J:260047
|
Gt(ROSA)26Sortm1(OVAL/fla,GFP)Vnce/Gt(ROSA)26Sor+
Lyz2tm1(cre)Ifo/Lyz2+
Pycardtm1Vmd/Pycardtm1Vmd
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6J
|
normal
growth/size/body region phenotype |
J:260047
|
|
normal
immune system phenotype |
J:260047
|
|
increased circulating interferon-gamma level |
J:260047
|
|
increased circulating interleukin-6 level |
J:260047
|
|
increased circulating tumor necrosis factor level |
J:260047
|
Gt(ROSA)26Sortm1(OVAL/fla,GFP)Vnce/Gt(ROSA)26Sor+
Lyz2tm1(cre)Ifo/Lyz2+
Nlrc4tm1Vmd/Nlrc4tm1Vmd
involves: 129P2/OlaHsd * C57BL/6J * C57BL/6NCrl
|
normal
immune system phenotype |
J:260047
|
|
normal
skeleton phenotype |
J:260047
|
Hfetm1Wsr/Hfetm1Wsr
Lyz2tm1(cre)Ifo/?
involves: 129P2/OlaHsd * C57BL/6
|
normal
homeostasis/metabolism phenotype |
J:132134
|
Hif1atm3Rsjo/Hif1atm3Rsjo
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ
|
abnormal leukocyte physiology |
J:117348
|
|
abnormal macrophage physiology |
J:107682
|
|
decreased inflammatory response |
J:107682
|
|
decreased susceptibility to induced arthritis |
J:107682
|
|
decreased tumor necrosis factor secretion |
J:107682
|
|
impaired macrophage chemotaxis |
J:107682
|
|
increased susceptibility to injury |
J:117348
|
Hif1atm3Rsjo/Hif1atm3Rsjo
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6
|
abnormal body temperature |
J:148597
|
|
abnormal systemic arterial blood pressure |
J:148597
|
|
decreased interleukin-1 alpha secretion |
J:148597
|
|
decreased interleukin-1 beta secretion |
J:148597
|
|
decreased interleukin-6 secretion |
J:148597
|
|
decreased interleukin-12 secretion |
J:148597
|
|
decreased susceptibility to endotoxin shock |
J:148597
|
|
decreased susceptibility to xenobiotic induced morbidity/mortality |
J:148597
|
|
decreased tumor necrosis factor secretion |
J:148597
|
Hmgb1tm1.1Ttg/Hmgb1tm1.1Ttg
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd
|
abnormal macrophage physiology |
J:205499
|
|
decreased macrophage cell number |
J:205499
|
|
normal
hematopoietic system phenotype |
J:205499
|
|
impaired macrophage phagocytosis |
J:205499
|
|
increased circulating interleukin-1 beta level |
J:205499
|
|
increased circulating interleukin-18 level |
J:205499
|
|
increased interleukin-1 beta secretion |
J:205499
|
|
increased interleukin-18 secretion |
J:205499
|
|
increased macrophage apoptosis |
J:205499
|
|
increased sensitivity to induced cell death |
J:205499
|
|
increased susceptibility to bacterial infection |
J:205499
|
|
increased susceptibility to endotoxin shock |
J:205499
|
Hmox1tm1.1Gkl/Hmox1tm1.1Gkl
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129 * 129P2/OlaHsd * BALB/cJ * C57BL/6
|
decreased interferon-beta secretion |
J:148498
|
|
decreased susceptibility to bacterial infection induced morbidity/mortality |
J:148498
|
|
decreased susceptibility to Paramyxoviridae infection |
J:148498
|
|
increased B cell number |
J:148498
|
|
increased CD4-positive, alpha-beta T cell number |
J:148498
|
|
increased CD8-positive, alpha-beta T cell number |
J:148498
|
|
increased circulating tumor necrosis factor level |
J:148498
|
|
increased granulocyte number |
J:148498
|
|
increased interferon-gamma secretion |
J:148498
|
|
increased macrophage cell number |
J:148498
|
|
increased splenocyte proliferation |
J:148498
|
|
increased susceptibility to experimental autoimmune encephalomyelitis |
J:148498
|
Hmox1tm1.1Hes/Hmox1tm1.1Hes
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6J * C57BL/6N
|
abnormal cellular respiration |
J:214639
|
|
abnormal metabolism |
J:214639
|
|
abnormal mitochondrial physiology |
J:214639
|
|
abnormal redox activity |
J:214639
|
|
decreased circulating free fatty acids level |
J:214639
|
|
decreased fat cell size |
J:214639
|
|
decreased inflammatory response |
J:214639
|
|
decreased interleukin-1 beta secretion |
J:214639
|
|
decreased interleukin-6 secretion |
J:214639
|
|
decreased susceptibility to diet-induced hepatic steatosis |
J:214639
|
|
decreased susceptibility to weight gain |
J:214639
|
|
decreased tumor necrosis factor secretion |
J:214639
|
|
improved glucose tolerance |
J:214639
|
|
increased energy expenditure |
J:214639
|
|
increased insulin sensitivity |
J:214639
|
Hnrnpa2b1tm1.1Caox/Hnrnpa2b1tm1.1Caox
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd
|
abnormal interferon level |
J:283622
|
|
decreased circulating interferon-beta level |
J:283622
|
|
decreased interferon-beta secretion |
J:283622
|
|
normal
immune system phenotype |
J:283622
|
|
increased susceptibility to Herpesvirales infection |
J:283622
|
|
increased susceptibility to Herpesvirales infection induced morbidity/mortality |
J:283622
|
Hsp90b1tm1Zhli/Hsp90b1tm1.1Zhli
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S/SvEv
|
abnormal cytokine secretion |
J:118427
|
|
abnormal inflammatory response |
J:118427
|
|
abnormal macrophage physiology |
J:118427
|
|
increased susceptibility to bacterial infection |
J:118427
|
|
premature death |
J:118427
|
Idh1tm1Mak/Idh1tm1Mak
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6
|
abnormal blood homeostasis |
J:186700
|
|
abnormal bone marrow cell morphology/development |
J:186700
|
|
abnormal bone marrow cell physiology |
J:186700
|
|
abnormal myeloblast morphology/development |
J:186700
|
|
abnormal spleen morphology |
J:186700
|
|
anemia |
J:186700
|
|
decreased B cell number |
J:186700
|
|
decreased bone marrow cell number |
J:186700
|
|
decreased CD4-positive, alpha-beta T cell number |
J:186700
|
|
decreased CD8-positive, alpha-beta T cell number |
J:186700
|
|
decreased common myeloid progenitor cell number |
J:186700
|
|
decreased hematocrit |
J:186700
|
|
decreased hemoglobin content |
J:186700
|
|
enlarged spleen |
J:186700
|
|
extramedullary hematopoiesis |
J:186700
|
|
normal
hematopoietic system phenotype |
J:186700
|
|
increased CD4-positive, alpha-beta T cell number |
J:186700
|
|
increased hematopoietic stem cell number |
J:186700
|
Idh1tm2Mak/Idh1tm2Mak
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6
|
abnormal blood homeostasis |
J:186700
|
|
abnormal bone marrow cell morphology/development |
J:186700
|
|
abnormal bone marrow cell physiology |
J:186700
|
|
abnormal myeloblast morphology/development |
J:186700
|
|
abnormal spleen morphology |
J:186700
|
|
anemia |
J:186700
|
|
decreased B cell number |
J:186700
|
|
decreased bone marrow cell number |
J:186700
|
|
decreased CD4-positive, alpha-beta T cell number |
J:186700
|
|
decreased CD8-positive, alpha-beta T cell number |
J:186700
|
|
decreased common myeloid progenitor cell number |
J:186700
|
|
decreased hematocrit |
J:186700
|
|
decreased hemoglobin content |
J:186700
|
|
enlarged spleen |
J:186700
|
|
extramedullary hematopoiesis |
J:186700
|
|
normal
hematopoietic system phenotype |
J:186700
|
|
increased CD4-positive, alpha-beta T cell number |
J:186700
|
|
increased hematopoietic stem cell number |
J:186700
|
Ifnb1tm2.1Lien/Ifnb1tm2.1Lien
Tyrc-2J/Tyrc-2J
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6
|
decreased circulating interferon-alpha level |
J:172226
|
|
decreased circulating interferon-beta level |
J:172226
|
|
decreased susceptibility to bacterial infection |
J:172226
|
Ikbipem1Bcgen/Ikbipem1Bcgen
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd
|
abnormal cytokine level |
J:282971
|
|
decreased macrophage cytokine production |
J:282971
|
|
increased circulating interleukin-6 level |
J:282971
|
|
increased circulating tumor necrosis factor level |
J:282971
|
|
increased susceptibility to bacterial infection induced morbidity/mortality |
J:282971
|
|
increased susceptibility to induced colitis |
J:282971
|
|
lung inflammation |
J:282971
|
Ikbkbtm1Lex/Ikbkbtm1Lex
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S/SvEvBrd
|
impaired macrophage chemotaxis |
J:159873
|
|
impaired neutrophil chemotaxis |
J:159873
|
|
impaired neutrophil recruitment |
J:159873
|
Ikbkbtm2Mka/Ikbkbtm2Mka
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129/Sv * 129P2/OlaHsd
|
increased macrophage apoptosis |
J:80159
|
Il1r1tm1Quan/Il1r1tm1Quan
Lyz2tm1(cre)Ifo/Lyz2tm1(cre)Ifo
involves: 129P2/OlaHsd * C57BL/6
|
abnormal inflammatory response |
J:219864
|
|
abnormal microglial cell activation |
J:219864
|
Il1r1tm1Roml/Il1r1tm1Roml
Nlrp3tm1Hhf/Nlrp3+
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129 * C57BL/6
|
normal
mortality/aging |
J:150054
|
|
skin inflammation |
J:150054
|
Il1rntm1.1Cga/Il1rntm1.1Cga
Lyz2tm1(cre)Ifo/Lyz2+
D1.Cg-Il1rntm1.1Cga Lyz2tm1(cre)Ifo
|
abnormal chemokine secretion |
J:162760
|
|
increased interferon-gamma secretion |
J:162760
|
|
increased interleukin-1 beta secretion |
J:162760
|
|
increased interleukin-6 secretion |
J:162760
|
|
increased interleukin-17 secretion |
J:162760
|
|
increased susceptibility to induced arthritis |
J:162760
|
|
increased T cell proliferation |
J:162760
|
Il4ratm1Fbb/Il4ratm2Fbb
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * BALB/c
|
abnormal immune system physiology |
J:114751
|
|
abnormal intestinal goblet cell morphology |
J:114751
|
|
abnormal macrophage physiology |
J:114751
|
|
decreased susceptibility to parasitic infection |
J:114751
|
|
granulomatous inflammation |
J:114751
|
|
increased susceptibility to parasitic infection |
J:114751
|
|
liver fibrosis |
J:114751
|
|
liver inflammation |
J:114751
|
|
premature death |
J:114751
|
|
weight loss |
J:114751
|
Il4ratm2Fbb/Il4ratm2Fbb
Lyz2tm1(cre)Ifo/?
involves: 129P2/OlaHsd * BALB/c
|
decreased core body temperature |
J:178294
|
|
decreased fatty acids level |
J:178294
|
Il6ratm1.1Drew/Il6ratm1.1Drew
Lyz2tm1(cre)Ifo/Lyz2+
involves: C57BL/6 * C57BL/6N * SJL
|
normal
immune system phenotype |
J:160966
|
Il6ratm1.1Jcbr/Il6ratm1.1Jcbr
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6
|
decreased circulating interleukin-1 beta level |
J:188445
|
|
decreased circulating tumor necrosis factor level |
J:188445
|
|
decreased susceptibility to parasitic infection |
J:188445
|
Il10tm2Roer/Il10tm2Roer
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6
|
abnormal cytokine secretion |
J:117122
|
|
abnormal inflammatory response |
J:117122
|
|
increased susceptibility to endotoxin shock |
J:117122
|
Il10ratm1.1Jack/Il10ratm1.1Jack
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * BALB/c * C57BL/6
|
abnormal chemokine level |
J:157787
|
|
abnormal cytokine level |
J:157787
|
|
increased circulating interferon-gamma level |
J:157787
|
|
increased circulating interleukin-1 alpha level |
J:157787
|
|
increased circulating interleukin-1 beta level |
J:157787
|
|
increased circulating interleukin-2 level |
J:157787
|
|
increased circulating interleukin-12 level |
J:157787
|
|
increased circulating interleukin-17 level |
J:157787
|
|
increased circulating tumor necrosis factor level |
J:157787
|
|
increased susceptibility to parasitic infection |
J:157787
|
Il12btm1Jm/Il12btm1Jm
Stat3tm2Aki/Stat3tm2Aki
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6
|
normal
digestive/alimentary phenotype |
J:83280
|
Il15ratm1Ama/Il15ratm2.1Ama
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6J
|
abnormal immune system physiology |
J:155298
|
|
abnormal NK cell differentiation |
J:155298
|
|
abnormal NK cell physiology |
J:155298
|
|
decreased CD8-positive, alpha-beta T cell number |
J:155298
|
|
decreased memory T cell number |
J:155298
|
|
decreased NK cell number |
J:155298
|
Il15ratm1Ama/Il15ratm2.1Ama
Lyz2tm1(cre)Ifo/0
Tg(Itgax-cre)1-1Reiz/0
involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * CBA
|
abnormal immune system physiology |
J:155298
|
|
decreased CD8-positive, alpha-beta T cell number |
J:155298
|
|
decreased memory T cell number |
J:155298
|
|
decreased NK cell number |
J:155298
|
Inpp5dtm1Rav/Inpp5dtm1.1Rav
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6
|
abnormal spleen marginal zone macrophage morphology |
J:119256
|
|
absent marginal zone B cells |
J:119256
|
|
enlarged spleen |
J:119256
|
Itgamtm1Myd/Itgamtm1Myd
Syktm1Tyb/Syktm1.2Tara
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S2/SvPas * 129S4/SvJae * C57BL/6
|
impaired granulocyte bactericidal activity |
J:155479
|
Itgavtm2Hyn/Itgavtm2.1Hyn
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * FVB
|
colitis |
J:125508
|
|
impaired macrophage phagocytosis |
J:125508
|
|
increased autoantibody level |
J:125508
|
Itgb3tm1Hyn/Itgb3tm1.1Wlbcr
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6
|
abnormal osteoclast differentiation |
J:224675
|
|
abnormal osteoclast morphology |
J:224675
|
|
abnormal tumor pathology |
J:224675
|
|
abnormal tumor susceptibility |
J:224675
|
|
decreased collagen level |
J:224675
|
|
decreased osteoclast cell number |
J:224675
|
|
increased bone mineral density |
J:224675
|
|
increased trabecular bone volume |
J:224675
|
|
osteopetrosis |
J:224675
|
Junbtm3Wag/Junbtm3Wag
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6
|
abnormal bone ossification |
J:88126
|
|
abnormal osteoclast morphology |
J:88126
|
|
abnormal trabecular bone morphology |
J:88126
|
Klf2tm2Ling/Klf2tm2Ling
Lyz2tm1(cre)Ifo/0
involves: 129P2/OlaHsd * 129S6/SvEvTac
|
decreased Ly6C low monocyte number |
J:239509
|
Klf4tm1Khk/Klf4tm1Khk
Lyz2tm1(cre)Ifo/0
involves: 129P2/OlaHsd * 129S6/SvEvTac
|
decreased Ly6C low monocyte number |
J:239509
|
Kmt2atm1.1(Sh3gl1)Lcc/Kmt2a+
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6
|
enlarged liver |
J:205605
|
|
enlarged lymph nodes |
J:205605
|
|
enlarged spleen |
J:205605
|
|
increased leukemia incidence |
J:205605
|
|
myeloid hyperplasia |
J:205605
|
|
premature death |
J:205605
|
Kmt2atm1.1Erns/Kmt2atm1.1Erns
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * SJL
|
normal
immune system phenotype |
J:147265
|
Krastm4Tyj/Kras+
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S4/SvJae
|
increased lung tumor incidence |
J:158937
|
|
increased lung weight |
J:158937
|
|
postnatal lethality, complete penetrance |
J:158937
|
Krastm4Tyj/Kras+
Pggt1btm1Mbrg/Pggt1b+
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129/Sv * 129P2/OlaHsd * C57BL/6
|
abnormal definitive hematopoiesis |
J:122107
|
|
abnormal liver morphology |
J:122107
|
|
abnormal spleen morphology |
J:122107
|
|
decreased lymphocyte cell number |
J:122107
|
|
increased lung adenocarcinoma incidence |
J:122107
|
|
increased lung adenoma incidence |
J:122107
|
|
increased lung tumor incidence |
J:122107
|
|
increased lung weight |
J:122107
|
|
increased neutrophil cell number |
J:122107
|
|
postnatal lethality, incomplete penetrance |
J:122107
|
|
respiratory distress |
J:122107
|
|
weight loss |
J:122107
|
Krastm4Tyj/Kras+
Pggt1btm1Mbrg/Pggt1btm1Mbrg
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129/Sv * 129P2/OlaHsd * C57BL/6
|
increased lung adenoma incidence |
J:122107
|
|
increased lung tumor incidence |
J:122107
|
|
increased lung weight |
J:122107
|
|
postnatal growth retardation |
J:122107
|
|
postnatal lethality, incomplete penetrance |
J:122107
|
Lancl2tm2c(KOMP)Wtsi/Lancl2tm2c(KOMP)Wtsi
Lyz2tm1(cre)Ifo/Lyz2+
involves: C57BL/6N
|
decreased macrophage cell number |
J:250673
|
|
decreased regulatory T cell number |
J:250673
|
|
decreased susceptibility to bacterial infection |
J:250673
|
Ldlrtm1Her/Ldlrtm1Her
Lrp1tm2Her/Lrp1tm2Her
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S7/SvEvBrd
|
impaired macrophage phagocytosis |
J:137404
|
Ldlrtm1Her/Ldlrtm1Her
Lrp1tm2Her/Lrp1tm2Her
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6J
|
abnormal microglial cell physiology |
J:144185
|
|
abnormal response to CNS ischemic injury |
J:144185
|
|
decreased cerebral infarct size |
J:144185
|
|
decreased susceptibility to ischemic brain injury |
J:144185
|
Ltbrtm1.1Thhe/Ltbrtm1.1Thhe
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6 * SJL
|
abnormal macrophage physiology |
J:183109
|
Ltbrtm1Avt/Ltbrtm1Avt
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd
|
increased susceptibility to bacterial infection |
J:158663
|
Lyz2tm1(cre)Ifo/Lyz2+
Pdcd10tm1Wami/Pdcd10tm1Wami
involves: 129 * 129P2/OlaHsd * C57BL/6
|
abnormal neutrophil morphology |
J:256076
|
|
abnormal neutrophil physiology |
J:256076
|
|
increased circulating creatinine level |
J:256076
|
|
renal tubular necrosis |
J:256076
|
Lyz2tm1(cre)Ifo/Lyz2+
Nfkbiztm1.1Muta/Nfkbiztm1.1Muta
involves: 129P2/OlaHsd * C57BL/6
|
normal
immune system phenotype |
J:194832
|
Lyz2tm1(cre)Ifo/Lyz2+
Pikfyvetm1b(EUCOMM)Hmgu/Pikfyvetm1b(EUCOMM)Hmgu
involves: 129P2/OlaHsd * C57BL/6N
|
abnormal alveolar macrophage morphology |
J:244776
|
|
abnormal alveolar macrophage physiology |
J:244776
|
|
decreased alveolar macrophage number |
J:244776
|
|
decreased regulatory T cell number |
J:244776
|
|
normal
immune system phenotype |
J:244776
|
|
increased eosinophil cell number |
J:244776
|
|
increased interleukin-4 secretion |
J:244776
|
|
increased interleukin-13 secretion |
J:244776
|
|
increased susceptibility to type I hypersensitivity reaction |
J:244776
|
Lyz2tm1(cre)Ifo/Lyz2+
St18tm1c(KOMP)Wtsi/St18tm1c(KOMP)Wtsi
involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N
|
abnormal retina blood vessel morphology |
J:298828
|
|
diarrhea |
J:298828
|
|
normal
homeostasis/metabolism phenotype |
J:298828
|
|
normal
immune system phenotype |
J:298828
|
|
increased circulating interleukin-1 beta level |
J:298828
|
|
increased inflammatory response |
J:298828
|
|
increased susceptibility to induced morbidity/mortality |
J:298828
|
|
increased susceptibility to weight loss |
J:298828
|
|
increased vascular permeability |
J:298828
|
|
slow postnatal weight gain |
J:298828
|
Lyz2tm1(cre)Ifo/Lyz2+
Selenowtm1c(EUCOMM)Wtsi/Selenowtm1c(EUCOMM)Wtsi
B6.Cg-Selenowtm1c(EUCOMM)Wtsi Lyz2tm1(cre)Ifo
|
abnormal osteoclast differentiation |
J:317012
|
|
decreased bone ossification |
J:317012
|
|
increased bone mass |
J:317012
|
Lyz2tm1(cre)Ifo/Lyz2+
Rnf217tm1.1Fudi/Rnf217tm1.1Fudi
involves: 129P2/OlaHsd
|
abnormal iron homeostasis |
J:315675
|
|
decreased spleen iron level |
J:315675
|
|
increased circulating iron level |
J:315675
|
Lyz2tm1(cre)Ifo/Lyz2+
Nsd3tm1.1Caox/Nsd3tm1.1Caox
involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J * SJL
|
decreased macrophage cytokine production |
J:251909
|
|
increased susceptibility to Riboviria infection |
J:251909
|
|
increased susceptibility to Riboviria infection induced morbidity/mortality |
J:251909
|
Lyz2tm1(cre)Ifo/Lyz2tm1(cre)Ifo
Nrrostm1Wouy/Nrrostm1Wouy
involves: 129P2/OlaHsd
|
abnormal cellular extravasation |
J:209569
|
|
increased susceptibility to experimental autoimmune encephalomyelitis |
J:209569
|
|
oxidative stress |
J:209569
|
Lyz2tm1(cre)Ifo/Lyz2tm1(cre)Ifo
Tg(Csf1r-HBEGF/mCherry)1Mnz/0
B6.Cg-Lyz2tm1(cre)Ifo Tg(Csf1r-HBEGF/mCherry)1Mnz/J
|
abnormal nociception after inflammation |
J:326965
|
|
decreased mechanical nociceptive threshold |
J:326965
|
|
decreased thermal nociceptive threshold |
J:326965
|
Lyz2tm1(cre)Ifo/0
Nup85tm1.1Yter/Nup85tm1.1Yter
involves: 129P2/OlaHsd * C57BL/6
|
decreased macrophage cell number |
J:292726
|
|
decreased tumor growth/size |
J:292726
|
Lyz2tm1(cre)Ifo/0
Pld4tm1.1Nemz/Pld4tm1.1Nemz
involves: 129 * 129P2/OlaHsd * C57BL/6J
|
normal
hematopoietic system phenotype |
J:281205
|
Lyz2tm1(HBEGF)Mtka/Lyz2+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
abnormal alveolar macrophage morphology |
J:145285
|
|
abnormal liver morphology |
J:145285
|
|
abnormal lung interstitium morphology |
J:145285
|
|
abnormal pulmonary alveolus morphology |
J:145285
|
|
abnormal surfactant secretion |
J:145285
|
|
absent type II pneumocytes |
J:145285
|
|
decreased locomotor activity |
J:145285
|
|
hunched posture |
J:145285
|
|
increased circulating lactate dehydrogenase level |
J:145285
|
|
lung hemorrhage |
J:145285
|
|
premature death |
J:145285
|
|
respiratory failure |
J:145285
|
|
ruffled hair |
J:145285
|
Map3k7tm1.1Gkl/Map3k7tm1.1Gkl
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6
|
decreased circulating interleukin-10 level |
J:211916
|
|
decreased interleukin-10 secretion |
J:211916
|
|
increased circulating interleukin-1 beta level |
J:211916
|
|
increased circulating tumor necrosis factor level |
J:211916
|
|
increased inflammatory response |
J:211916
|
|
increased interleukin-1 beta secretion |
J:211916
|
|
increased interleukin-6 secretion |
J:211916
|
|
increased interleukin-10 secretion |
J:211916
|
|
increased susceptibility to endotoxin shock |
J:211916
|
|
increased susceptibility to induced morbidity/mortality |
J:211916
|
|
increased tumor necrosis factor secretion |
J:211916
|
Map3k8tm1.1Gkl/Map3k8tm1.1Gkl
Lyz2tm1(cre)Ifo/Lyz2+
involves: C57BL/6 * FVB/N
|
normal
homeostasis/metabolism phenotype |
J:193546
|
|
normal
neoplasm |
J:193546
|
Mapk8tm1Rjd/Mapk8tm1Rjd
Mapk9tm2.1Rjd/Mapk9tm2.1Rjd
Lyz2tm1(cre)Ifo/Lyz2+
B6J.Cg-Lyz2tm1(cre)Ifo Mapk9tm2.1Rjd Mapk8tm1Rjd
|
abnormal chemokine level |
J:192551
|
|
abnormal circulating chemokine level |
J:192551
|
|
abnormal circulating cytokine level |
J:192551
|
|
abnormal gluconeogenesis |
J:192551
|
|
abnormal glucose homeostasis |
J:192551
|
|
abnormal glycogen homeostasis |
J:192551
|
|
abnormal lipid homeostasis |
J:192551
|
|
abnormal macrophage differentiation |
J:192551
|
|
abnormal macrophage physiology |
J:192551
|
|
decreased circulating glucose level |
J:192551
|
|
decreased circulating insulin level |
J:192551
|
|
decreased inflammatory response |
J:192551
|
|
decreased lean body mass |
J:192551
|
|
decreased macrophage cell number |
J:192551
|
|
decreased macrophage cytokine production |
J:192551
|
|
decreased pancreatic beta cell proliferation |
J:192551
|
|
normal
homeostasis/metabolism phenotype |
J:192551
|
|
impaired macrophage chemotaxis |
J:192551
|
|
improved glucose tolerance |
J:192551
|
|
increased insulin secretion |
J:192551
|
|
increased insulin sensitivity |
J:192551
|
|
small pancreatic islets |
J:192551
|
Mcl1tm1Ywh/Mcl1tm1Ywh
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S4/SvJae * 129S6/SvEvTac * C57BL/6
|
abnormal neutrophil physiology |
J:137502
|
|
decreased granulocyte number |
J:137502
|
|
decreased neutrophil cell number |
J:137502
|
|
normal
immune system phenotype |
J:137502
|
|
impaired neutrophil recruitment |
J:137502
|
|
increased eosinophil cell number |
J:137502
|
Mef2ctm1Jjs/Mef2ctm1Jjs
Mir223tm1Fcam/Mir223tm1Fcam
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129 * C57BL/6
|
abnormal neutrophil differentiation |
J:140009
|
|
abnormal neutrophil physiology |
J:140009
|
|
increased neutrophil cell number |
J:140009
|
Ms4a7em1Jddl/Ms4a7em1Jddl
Lyz2tm1(cre)Ifo/Lyz2+
B6.Cg-Lyz2tm1(cre)Ifo Ms4a7em1Jddl
|
abnormal liver morphology |
J:347975
|
|
decreased circulating alanine transaminase level |
J:347975
|
|
decreased circulating aspartate transaminase level |
J:347975
|
|
decreased circulating tumor necrosis factor level |
J:347975
|
|
decreased cytokine level |
J:347975
|
|
decreased susceptibility to diet-induced hepatic steatosis |
J:347975
|
Myd88tm1Hlz/Myd88tm1Hlz
Lyz2tm1(cre)Ifo/Lyz2+
B6.129P2-Myd88tm1Hlz Lyz2tm1(cre)Ifo
|
abnormal circulating chemokine level |
J:188968
|
|
decreased CXCL10 level |
J:188968
|
|
normal
immune system phenotype |
J:188968
|
|
increased circulating alanine transaminase level |
J:188968
|
|
increased circulating aspartate transaminase level |
J:188968
|
|
increased circulating tumor necrosis factor level |
J:188968
|
|
increased susceptibility to injury |
J:188968
|
Myo18atm1c(KOMP)Wtsi/Myo18atm1c(KOMP)Wtsi
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6N
|
normal
immune system phenotype |
J:277320
|
n-TUtca2tm2Mym/n-TUtca2tm2.1Mym
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6 * DBA/2
|
increased apoptosis |
J:130723
|
|
increased cellular sensitivity to oxidative stress |
J:130723
|
|
premature death |
J:130723
|
Naipctm1Kmma/Naipctm1Kmma
Lyz2tm1(cre)Ifo/Lyz2+
B6.Cg-Lyz2tm1(cre)Ifo Naipctm1Kmma
|
decreased susceptibility to induced colitis |
J:222114
|
|
normal
neoplasm |
J:222114
|
Nfat5tm1.1Itl/Nfat5tm1.1Itl
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6NTac * FVB/N
|
abnormal chloride level |
J:201429
|
|
abnormal lymphatic vessel morphology |
J:201429
|
|
increased mean systemic arterial blood pressure |
J:201429
|
Nfatc1tm3Glm/Nfatc1tm3Glm
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6
|
normal
skeleton phenotype |
J:144598
|
Nfe2l2tm1Mym/Nfe2l2tm1Mym
n-TUtca2tm2Mym/n-TUtca2tm2.1Mym
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6 * DBA/2
|
increased apoptosis |
J:130723
|
|
increased cellular sensitivity to hydrogen peroxide |
J:130723
|
|
increased cellular sensitivity to oxidative stress |
J:130723
|
Nfkbiatm1Kbp/Nfkbiatm1Kbp
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6
|
normal
hematopoietic system phenotype |
J:97945
|
Nlrp3tm1Flv/Nlrp3tm1Hhf
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129 * C57BL/6
|
increased inflammatory response |
J:150054
|
|
postnatal lethality, complete penetrance |
J:150054
|
Nlrp3tm1Hhf/Nlrp3+
Rag1tm1Mom/Rag1tm1Mom
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129/Sv * 129P2/OlaHsd * C57BL/6
|
absent B cells |
J:150054
|
|
absent T cells |
J:150054
|
|
postnatal lethality, complete penetrance |
J:150054
|
|
reddish skin |
J:150054
|
|
scaly skin |
J:150054
|
|
slow postnatal weight gain |
J:150054
|
Nlrp3tm1Hhf/Nlrp3+
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129/Sv * 129P2/OlaHsd * C57BL/6
|
abnormal circulating chemokine level |
J:150054
|
|
abnormal circulating cytokine level |
J:150054
|
|
abnormal intestine morphology |
J:150054
|
|
abnormal kidney morphology |
J:150054
|
|
hairless |
J:150054
|
|
increased circulating interleukin-1 beta level |
J:150054
|
|
increased circulating interleukin-6 level |
J:150054
|
|
increased circulating interleukin-18 level |
J:150054
|
|
increased circulating tumor necrosis factor level |
J:150054
|
|
increased inflammatory response |
J:150054
|
|
increased leukocyte cell number |
J:150054
|
|
increased neutrophil cell number |
J:150054
|
|
postnatal lethality, complete penetrance |
J:150054
|
|
reddish skin |
J:150054
|
|
scaly skin |
J:150054
|
|
slow postnatal weight gain |
J:150054
|
|
thrombocytosis |
J:150054
|
Nlrp3tm1Hhf/Nlrp3+
Pycardtm1Flv/Pycardtm1Flv
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129 * C57BL/6
|
no abnormal phenotype detected |
J:150054
|
Nlrp3tm2Hhf/Nlrp3+
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129/Sv * 129P2/OlaHsd * C57BL/6
|
perinatal lethality, complete penetrance |
J:150054
|
Notch2tm2.1Ecan/Notch2tm2.1Ecan
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6J
|
normal
skeleton phenotype |
J:246017
|
Notch2tm2.1Ecan/Notch2tm2.1Ecan
Lyz2tm1(cre)Ifo/Lyz2tm1(cre)Ifo
involves: 129P2/OlaHsd * C57BL/6J
|
normal
skeleton phenotype |
J:246017
|
Nr3c1tm2.1Ljm/Nr3c1tm2.1Ljm
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S6/SvEvTac
|
abnormal interleukin-6 secretion |
J:197150
|
|
abnormal monocyte cell number |
J:197150
|
|
abnormal response to CNS ischemic injury |
J:197150
|
|
decreased susceptibility to neuronal excitotoxicity |
J:197150
|
|
increased interleukin-1 beta secretion |
J:197150
|
Nr3c1tm2Gsc/Nr3c1tm2Gsc
Lyz2tm1(cre)Ifo/Lyz2+
B6.129P2-Lyz2tm1(cre)Ifo Nr3c1tm2Gsc
|
normal
immune system phenotype |
J:137157
|
Nr3c1tm2Gsc/Nr3c1tm2Gsc
Lyz2tm1(cre)Ifo/Lyz2+
C.129P2-Lyz2tm1(cre)Ifo Nr3c1tm2Gsc
|
normal
skeleton phenotype |
J:160669
|
Nucb2tm1.1Vdix/Nucb2tm1.1Vdix
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6
|
normal
growth/size/body region phenotype |
J:270674
|
|
impaired glucose tolerance |
J:270674
|
|
insulin resistance |
J:270674
|
P4hbtm1.1Geno/P4hbtm1.2Geno
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd
|
decreased neutrophil cell number |
J:197556
|
|
impaired neutrophil recruitment |
J:197556
|
Pcyt1atm1Irt/Pcyt1atm1Irt
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129 * C57BL/6J
|
abnormal immune cell physiology |
J:65639
|
|
abnormal macrophage physiology |
J:65639
|
Plekhf1tm1.1Caox/Plekhf1tm1.1Caox
Lyz2tm1(cre)Ifo/Lyz2+
B6.Cg-Plekhf1tm1.1Caox Lyz2tm1(cre)Ifo
|
abnormal cytokine secretion |
J:277440
|
|
abnormal endocytosis |
J:277440
|
|
abnormal macrophage physiology |
J:277440
|
|
decreased circulating interferon-beta level |
J:277440
|
|
decreased circulating interleukin-6 level |
J:277440
|
|
decreased circulating tumor necrosis factor level |
J:277440
|
|
increased susceptibility to bacterial infection |
J:277440
|
|
increased susceptibility to bacterial infection induced morbidity/mortality |
J:277440
|
Pmltm1(PML/RARA)Ley/Pml+
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * BALB/cJ * C57BL/6
|
normal
hematopoietic system phenotype |
J:172024
|
|
increased leukemia incidence |
J:172024
|
Ppargtm1.1Gonz/Ppargtm1.1Gonz
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6
|
abnormal kidney morphology |
J:168799
|
|
abnormal macrophage activation involved in immune response |
J:168799
|
|
abnormal nephron morphology |
J:168799
|
|
abnormal peritoneal macrophage morphology |
J:168799
|
|
abnormal podocyte foot process morphology |
J:168799
|
|
abnormal renal glomerulus morphology |
J:168799
|
|
albuminuria |
J:168799
|
|
enlarged kidney |
J:168799
|
|
expanded mesangial matrix |
J:168799
|
|
fused podocyte foot processes |
J:168799
|
|
glomerulonephritis |
J:168799
|
|
impaired macrophage phagocytosis |
J:168799
|
|
increased anti-double stranded DNA antibody level |
J:168799
|
|
increased anti-nuclear antigen antibody level |
J:168799
|
|
increased anti-single stranded DNA antibody level |
J:168799
|
|
increased autoantibody level |
J:168799
|
|
increased circulating creatine level |
J:168799
|
|
increased IgG level |
J:168799
|
|
increased IgM level |
J:168799
|
|
increased kidney weight |
J:168799
|
|
increased mesangial cell number |
J:168799
|
|
increased renal glomerulus apoptosis |
J:168799
|
|
increased renal glomerulus basement membrane thickness |
J:168799
|
|
increased urine protein level |
J:168799
|
|
renal glomerulus hypertrophy |
J:168799
|
Prmt9em1Cya/Prmt9em1Cya
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6N
|
decreased susceptibility to viral infection |
J:328263
|
|
increased circulating interferon-beta level |
J:328263
|
|
increased interferon-beta secretion |
J:328263
|
Ptentm1Hwu/Ptentm1Hwu
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S4/SvJae
|
abnormal alveolar macrophage morphology |
J:148947
|
|
abnormal cytokine level |
J:148947
|
|
abnormal macrophage chemotaxis |
J:148947
|
|
abnormal neutrophil physiology |
J:114699,
J:145331,
J:148947
|
|
decreased susceptibility to bacterial infection |
J:148947
|
|
decreased susceptibility to bacterial infection induced morbidity/mortality |
J:148947
|
|
impaired neutrophil recruitment |
J:148947
|
|
increased susceptibility to bacterial infection |
J:148947
|
|
increased susceptibility to bacterial infection induced morbidity/mortality |
J:148947
|
|
lung inflammation |
J:148947
|
|
pulmonary edema |
J:148947
|
Ptgestm1.1Gaf/Ptgestm1.1Gaf
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129 * C57BL/6
|
abnormal leukocyte physiology |
J:210141
|
|
abnormal vascular wound healing |
J:210141
|
|
decreased prostaglandin level |
J:210141
|
|
increased leukocyte cell number |
J:210141
|
|
increased prostaglandin level |
J:210141
|
Ptpmt1tm2.1Ckq/Ptpmt1tm2.1Ckq
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * SJL
|
abnormal aerobic respiration |
J:194929
|
|
normal
hematopoietic system phenotype |
J:194929
|
|
normal
immune system phenotype |
J:194929
|
Ptpn11tm1Ckq/Ptpn11+
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J
|
increased acute promyelocytic leukemia incidence |
J:177285
|
|
myeloid hyperplasia |
J:177285
|
|
premature death |
J:177285
|
Pycardtm1Ayaz/Pycardtm1Ayaz
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6J
|
decreased incidence of tumors by chemical induction |
J:191239
|
|
decreased interleukin-1 alpha secretion |
J:191239
|
|
decreased interleukin-1 beta secretion |
J:191239
|
|
decreased interleukin-6 secretion |
J:191239
|
|
decreased tumor necrosis factor secretion |
J:191239
|
Rac1tm1Djk/Rac1tm1.1Djk
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6
|
decreased acute inflammation |
J:83457
|
|
decreased leukocyte cell number |
J:83457
|
|
decreased neutrophil cell number |
J:83457
|
|
impaired neutrophil chemotaxis |
J:83457
|
|
impaired neutrophil recruitment |
J:83457
|
Rb1cc1tm1.1Guan/Rb1cc1tm1.1Guan
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd
|
normal
immune system phenotype |
J:235399
|
Rfx5tm1Ifo/Rfx5tm1.1Ifo
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129 * C57BL/6 * C.B-20
|
abnormal MHC II cell surface expression on macrophages |
J:67924
|
Rnf146tm1.1Rtpl/Rnf146tm1.1Rtpl
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6J
|
abnormal compact bone morphology |
J:243612
|
|
abnormal osteoclast differentiation |
J:243612
|
|
decreased bone mineral density |
J:243612
|
|
decreased bone trabecula number |
J:243612
|
|
decreased compact bone thickness |
J:243612
|
|
decreased trabecular bone mass |
J:243612
|
|
decreased trabecular bone volume |
J:243612
|
|
increased bone trabecular spacing |
J:243612
|
|
increased circulating tumor necrosis factor level |
J:243612
|
|
increased osteoclast cell number |
J:243612
|
|
normal
skeleton phenotype |
J:243612
|
Rnf146tm1.1Rtpl/Rnf146tm1.1Rtpl
Sh3bp2tm1c(KOMP)Wtsi/Sh3bp2tm1c(KOMP)Wtsi
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6J * C57BL/6N
|
normal
skeleton phenotype |
J:243612
|
Rpl13atm1.1Mazu/Rpl13atm1.1Mazu
Lyz2tm1(cre)Ifo/Lyz2+
involves: C57BL/6
|
abnormal cytokine level |
J:194920
|
|
abnormal lung morphology |
J:194920
|
|
abnormal macrophage chemotaxis |
J:194920
|
|
decreased locomotor activity |
J:194920
|
|
increased blood urea nitrogen level |
J:194920
|
|
increased circulating aspartate transaminase level |
J:194920
|
|
increased circulating tumor necrosis factor level |
J:194920
|
|
premature death |
J:194920
|
|
tachypnea |
J:194920
|
Rxratm1Krc/Rxratm1Krc
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6
|
abnormal kidney morphology |
J:168799
|
|
abnormal macrophage activation involved in immune response |
J:168799
|
|
abnormal nephron morphology |
J:168799
|
|
abnormal peritoneal macrophage morphology |
J:168799
|
|
abnormal podocyte foot process morphology |
J:168799
|
|
abnormal renal glomerulus morphology |
J:168799
|
|
albuminuria |
J:168799
|
|
enlarged kidney |
J:168799
|
|
expanded mesangial matrix |
J:168799
|
|
fused podocyte foot processes |
J:168799
|
|
glomerulonephritis |
J:168799
|
|
impaired macrophage phagocytosis |
J:168799
|
|
increased anti-double stranded DNA antibody level |
J:168799
|
|
increased anti-nuclear antigen antibody level |
J:168799
|
|
increased anti-single stranded DNA antibody level |
J:168799
|
|
increased autoantibody level |
J:168799
|
|
increased circulating creatine level |
J:168799
|
|
increased IgG level |
J:168799
|
|
increased IgM level |
J:168799
|
|
increased kidney weight |
J:168799
|
|
increased mesangial cell number |
J:168799
|
|
increased renal glomerulus apoptosis |
J:168799
|
|
increased renal glomerulus basement membrane thickness |
J:168799
|
|
increased urine protein level |
J:168799
|
|
renal glomerulus hypertrophy |
J:168799
|
Slc3a2tm1.1Yait/Slc3a2tm1.1Yait
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6NCrSlc
|
abnormal macrophage antigen presentation |
J:188365
|
|
abnormal macrophage differentiation |
J:188365
|
|
abnormal macrophage morphology |
J:188365
|
|
abnormal macrophage physiology |
J:188365
|
|
impaired macrophage phagocytosis |
J:188365
|
Socs3tm1Ayos/Socs3tm1Ayos
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129 * C57BL/6
|
decreased susceptibility to endotoxin shock |
J:92040
|
Socs3tm1Wsa/Socs3tm2Wsa
Lyz2tm1(cre)Ifo/?
involves: 129P2/OlaHsd * C57BL/6
|
abnormal macrophage physiology |
J:83645
|
Sqstm1tm2.1Jmos/Sqstm1tm2.1Jmos
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd
|
normal
cellular phenotype |
J:194291
|
|
normal
growth/size/body region phenotype |
J:194291
|
|
normal
homeostasis/metabolism phenotype |
J:194291
|
Stat1tm1Rds/Stat1tm1Rds
Stat3tm2Aki/Stat3tm2Aki
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129/Sv * 129P2/OlaHsd * C57BL/6
|
abnormal colon morphology |
J:83280
|
|
colitis |
J:83280
|
|
increased CD4-positive, alpha-beta T cell number |
J:83280
|
|
increased interferon-gamma secretion |
J:83280
|
|
increased interleukin-6 secretion |
J:83280
|
|
increased tumor necrosis factor secretion |
J:83280
|
Stat3tm2Aki/Stat3tm2Aki
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6
|
abnormal colon morphology |
J:83280
|
|
colitis |
J:83280
|
|
increased CD4-positive, alpha-beta T cell number |
J:83280
|
|
increased dendritic cell number |
J:83280
|
|
increased interferon-gamma secretion |
J:83280
|
|
increased interleukin-12 secretion |
J:83280
|
|
increased macrophage cell number |
J:83280
|
Stat3tm2Aki/Stat3tm2Aki
Tlr4tm1Aki/Tlr4tm1Aki
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6
|
colitis |
J:83280
|
|
decreased interferon-gamma secretion |
J:83280
|
|
decreased susceptibility to endotoxin shock |
J:83280
|
Stat3tm2Aki/Stat3tm2Aki
Tnftm1Sek/Tnftm1Sek
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6 * CBA
|
colitis |
J:83280
|
|
increased interferon-gamma secretion |
J:83280
|
|
increased interleukin-6 secretion |
J:83280
|
|
increased interleukin-12b secretion |
J:83280
|
Stk11tm1Keis/Stk11tm1Keis
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd
|
increased circulating interleukin-10 level |
J:191723
|
Syktm1.1Nns/Syktm1.1Nns
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd
|
normal
homeostasis/metabolism phenotype |
J:181715
|
|
normal
immune system phenotype |
J:181715
|
|
normal
mortality/aging |
J:181715
|
Syktm1Tyb/Syktm1.2Tara
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6
|
abnormal neutrophil physiology |
J:155479
|
|
impaired granulocyte bactericidal activity |
J:155479
|
Tab2tm2.1Aki/Tab2tm2.1Aki
Tab3tm1Aki/Tab3tm1Aki
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6
|
normal
immune system phenotype |
J:195289
|
Tfpitm1.1Rdsi/Tfpitm1.1Rdsi
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S4/SvJaeSor * 129S6/SvEvTac * BALB/cJ * C57BL/6
|
abnormal circulating protein level |
J:164530
|
Thbdtm1.1Hlwu/Thbdtm1.1Hlwu
Lyz2tm1(cre)Ifo/Lyz2+
B6.129-Thbdtm1.1Hlwu Lyz2tm1(cre)Ifo
|
decreased circulating interleukin-6 level |
J:188879
|
|
decreased circulating tumor necrosis factor level |
J:188879
|
|
decreased susceptibility to bacterial infection |
J:188879
|
|
decreased susceptibility to bacterial infection induced morbidity/mortality |
J:188879
|
|
decreased susceptibility to induced morbidity/mortality |
J:188879
|
|
decreased susceptibility to injury |
J:188879
|
|
decreased tumor necrosis factor secretion |
J:188879
|
Tnftm1.1Sned/Tnftm1.1Sned
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129 * 129P2/OlaHsd * C57BL/6
|
abnormal chemokine secretion |
J:95684
|
|
decreased circulating tumor necrosis factor level |
J:95684
|
|
decreased susceptibility to autoimmune disorder |
J:95684
|
|
decreased susceptibility to endotoxin shock |
J:95684
|
|
hepatic necrosis |
J:95684
|
|
increased susceptibility to bacterial infection |
J:95684
|
|
increased susceptibility to induced morbidity/mortality |
J:95684
|
Tnftm2.1Gkl/Tnf+
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S/SvEv * 129S6/SvEvTac * C57BL/6J
|
weight loss |
J:108572
|
Tnftm2.1Gkl/Tnftm2.1Gkl
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6J
|
weight loss |
J:108572
|
Traf6tm1.1Mpa/Traf6tm1.1Mpa
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6
|
decreased circulating interleukin-6 level |
J:145306
|
|
decreased susceptibility to injury |
J:145306
|
Trim58tm2313.1Arte/Trim58tm2313.1Arte
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6N
|
increased susceptibility to induced colitis |
J:279270
|
Ube2ntm1Aki/Ube2ntm1Aki
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6
|
abnormal macrophage physiology |
J:112287
|
Upf2tm1Btp/Upf2tm1Btp
Lyz2tm1(cre)Ifo/?
involves: 129P2/OlaHsd * C57BL/6 * CBA
|
normal
immune system phenotype |
J:134765
|
Vegfatm2Gne/Vegfatm2Gne
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129/Sv * 129P2/OlaHsd
|
decreased inflammatory response |
J:107682
|
Vegfatm2Gne/Vegfatm2Gne
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129/Sv * 129P2/OlaHsd * C57BL/6
|
normal
immune system phenotype |
J:148597
|
|
normal
mortality/aging |
J:148597
|
Vegfatm2Gne/Vegfatm2Gne
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129/Sv * 129P2/OlaHsd * FVB/N
|
abnormal wound healing |
J:189044
|
Vegfatm2Gne/Vegfatm2Gne
Lyz2tm1(cre)Ifo/Lyz2+
Tg(KRT14-cre)1Cgn/0
involves: 129 * C57BL/6 * CBA * FVB/N
|
abnormal wound healing |
J:189044
|
Vhltm1Jae/Vhltm1Jae
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S4/SvJae
|
increased inflammatory response |
J:107682
|
Zc3h12atm1c(EUCOMM)Hmgu/Zc3h12atm1c(EUCOMM)Hmgu
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6N
|
increased inflammatory response |
J:304105
|
|
normal
liver/biliary system phenotype |
J:304105
|
Zc3h12ctm2c(EUCOMM)Hmgu/Zc3h12ctm2c(EUCOMM)Hmgu
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6N
|
enlarged lymph nodes |
J:277714
|
|
increased B cell number |
J:277714
|
|
increased CD4-positive, alpha-beta T cell number |
J:277714
|
|
increased effector memory CD8-positive, alpha-beta T cell number |
J:277714
|
|
increased immature B cell number |
J:277714
|
|
increased marginal zone B cell number |
J:277714
|
Zfp36tm4.1Pjb/Zfp36tm4.1Pjb
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N
|
abnormal myocardium layer morphology |
J:188677
|
|
abnormal pilomotor reflex |
J:188677
|
|
abnormal renal glomerulus morphology |
J:188677
|
|
abnormal small intestine morphology |
J:188677
|
|
alveolitis |
J:188677
|
|
autoimmune arthritis |
J:188677
|
|
decreased body temperature |
J:188677
|
|
decreased body weight |
J:188677
|
|
enlarged lymph nodes |
J:188677
|
|
enlarged spleen |
J:188677
|
|
focal hepatic necrosis |
J:188677
|
|
increased blood urea nitrogen level |
J:188677
|
|
increased circulating alanine transaminase level |
J:188677
|
|
increased circulating lactate dehydrogenase level |
J:188677
|
|
increased circulating tumor necrosis factor level |
J:188677
|
|
increased inflammatory response |
J:188677
|
|
increased spleen weight |
J:188677
|
|
increased susceptibility to endotoxin shock |
J:188677
|
|
lethargy |
J:188677
|
|
normal
mortality/aging |
J:188677
|
|
tachypnea |
J:188677
|
Analysis Tools
Excel File